StockMarketWire.com - Tristel has hiked its H1 pretax profit, before share-based payments, to GBP1.5m, from GBP1.1m. Interim divided was 1.14p a share, from 0.585p. Revenue gained 8% to GBP8m, from GBP7.4m.

CEO Paul Swinney said:

"We are pleased to report strong half-on-half profits growth, which has translated into an increase in cash and a substantial increase in the interim dividend.

"Overseas sales accounted for 36% of total revenue and increased by 20% during the period. Our international expansion continues with many regulatory approvals awaited, not only in healthcare markets in which we already sell, but also in countries in which we have no presence.

"This includes the United States. Two products have been selected for our approach to the US market, and we are in dialogue with the FDA in preparation for a full regulatory approval submission during 2016."






Story provided by StockMarketWire.com